comparemela.com
Home
Live Updates
Dermavant Sciences: Dermavant to Present New Data from the Phase 3 PSOARING 3 Long-Term Extension Trial of Tapinarof Cream for Adults with Plaque Psoriasis at the 2022 American Academy of Dermatology Annual Meeting : comparemela.com
Dermavant Sciences: Dermavant to Present New Data from the Phase 3 PSOARING 3 Long-Term Extension Trial of Tapinarof Cream for Adults with Plaque Psoriasis at the 2022 American Academy of Dermatology Annual Meeting
- Two posters will present data across secondary efficacy outcomes, quality of life and tolerability scores of tapinarof cream 1% once daily - Dermavant Sciences, a clinical-stage biopharmaceutical
Related Keywords
United States
,
Boston
,
Massachusetts
,
America
,
American
,
Laurence Watts
,
Melinda Gooderham
,
Annam Tallman
,
Angela Salerno Robin
,
Philipm Brown
,
Laurak Ferris
,
Kostenloser Wertpapierhandel
,
Aprilw Armstrong
,
Benjamin Ehst
,
Davids Rubenstein
,
Seemalr Desai
,
Program For Tapinarof
,
Exhibition Center
,
Twitter
,
Drug Administration
,
American Academy Of Dermatology
,
Boston Convention
,
Roivant Sciences
,
Dermavant Sciences
,
Linkedin Dermavant Sciences
,
Annual Meeting
,
New Drug Application
,
Prescription Drug User Fee Act
,
Tapinarof Cream
,
Once Daily
,
Plaque Psoriasis
,
Secondary Efficacy Outcomes
,
Long Term Extension
,
Psoriasis Area
,
Severity Index
,
Linda Stein Gold
,
Jerry Bagel
,
Dermatology Life Quality Index
,
Local Tolerability Scores
,
Leon Kircik
,
North America
,
Vice President
,
Media Relations
,
Dermavant
,
Ciences
,
Present
,
Data
,
Rom
,
Hase
,
Soaring
,
Song
,
Term
,
Extension
,
Trial
,
Tapinarof
,
Cream
,
Adults
,
Plaque
,
Psoriasis
,
022
,
Academy
,
Ermatology
,
Nnual
,
Meeting
,
comparemela.com © 2020. All Rights Reserved.